Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in Mesothelioma

Brief summary (registry, in English)

To evaluate whether co-administration of an anti-p40 antibody reduces the incidence of severe (grade ≥3) irAEs in patients receiving dual ICB with anti–PD-1 and anti–CTLA-4 antibodies.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 42
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pleural mesothelioma that cannot be removed by surgery and who can receive dual immune checkpoint treatment. It tests whether adding an anti-p40 antibody lowers severe side effects.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Pleural mesothelioma that cannot be removed by surgery, confirmed by histology or cytology.

Earlier treatment

No immunomodulatory drugs within 14 days before starting immune checkpoint treatment.

Main reasons for not taking part

• Immunomodulatory drugs within 14 days before starting immune checkpoint treatment
• Known hypersensitivity to ustekinumab
• Active (mycobacterial) infection
• Chronic, recurring infections

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details